|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 309.2 INR | -0.51% |
|
-3.19% | +23.87% |
| 24/05 | INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh | RE |
| 24/05 | Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea | MT |
Biocon Limited reported earnings results for the fourth quarter ended March 31, 2024. For the fourth quarter, the company reported revenue was INR 39,657 million compared to INR 39,288 million a year ago. Net income was INR 1,355 million compared to INR 3,132 million a year ago.
Basic earnings per share from continuing operations was INR 1.13 compared to INR 2.62 a year ago. Diluted earnings per share from continuing operations was INR 1.13 compared to INR 2.62 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +23.87% | 4.42B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
BIOCON LIMITED 
